MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin growth accelerates
Q3 FY2026 selling, general & admin of $34.3M rose 636.6% year over year, ahead of the +263.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 244.8% from the prior quarter. Over 3 fiscal years it compounded at +71.2% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +75.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $34.3M+244.8% QoQ
- Last fiscal yearDec 2025
- $18.9M+75.3% YoY
- LTMSep 2026
- $59.07M+263.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +636.6% | -100.0% | -736.6 pp |
| 1 year | +75.3% | -100.0% | -175.3 pp |
| 3-year CAGR | +71.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 18.9M USD
- Year-over-year change
- +75.3%
- 3-year CAGR
- +71.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.9M | +75.3% |
| FY2024 | 2024-12-31 | 10.78M | +59.1% |
| FY2023 | 2023-12-31 | 6.78M | +80.0% |
| FY2022 | 2022-12-31 | 3.76M | — |
Selling, General & Admin vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +263.5% is the highest of 8, against a peer median of +21.4%.
- Over three fiscal years its annual growth of +71.2% compares with a peer median of +17.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | €598.18M EUR | +52.7% | +26.4% | 49.5% | |
| LTM Sep 2026 | $255.27M USD | +45.4% | +28.4% | 90.9% | |
| LTM Mar 2026 | $191.5M USD | +13.2% | +9.8% | 60.8% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $59.07M USD | +263.5% | +71.2% | — |
| LTM Jun 2026 | $50.71M USD | -11.8% | +44.2% | — | |
KLRAKailera Therapeutics, Inc. | FY2025 | $49.23M USD | — | — | — |
| LTM Mar 2026 | $30.16M USD | +39.3% | +17.9% | 83769.4% | |
| LTM Mar 2026 | $16.17M USD | -36.6% | -2.6% | — | |
| LTM Mar 2026 | $8.48M USD | +21.4% | -17.7% | — | |
| Peer median (excluding MBX) | — | +21.4% | +17.9% | 75.9% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 248K |
| Gross Profit | 0 | 0 | 0 | (248K) |
| Gross Margin | — | — | — | — |
| Research & Development | 21.4M | 28.53M | 57.42M | 79.16M |
| Selling, General & Admin | 3.76M | 6.78M | 10.78M | 18.9M |
| Operating Expenses | 25.16M | 35.31M | 68.19M | 98.06M |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| EBITDA | (25.71M) | (32.41M) | (61.68M) | (86.72M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (25.16M) | (35.31M) | (68.19M) | (98.06M) |
| Operating Margin | — | — | — | — |
| Interest Income | 372K | 2.75M | 6.27M | 11.08M |
| Interest Expense | 374K | 0 | 0 | 0 |
| Other Income / Expenses | (974K) | 2.75M | 6.27M | 11.08M |
| Income Before Tax | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.82) | (1.02) | (1.85) | (2.38) |
| EPS (Diluted) | (0.82) | (1.02) | (1.85) | (2.38) |
| Weighted Avg Shares | 31.85M | 31.85M | 33.39M | 36.51M |
| Weighted Avg Shares (Diluted) | 31.85M | 31.85M | 33.39M | 36.51M |
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.